<html xmlns:v="urn:schemas-microsoft-com:vml" xmlns:o="urn:schemas-microsoft-com:office:office" xmlns:w="urn:schemas-microsoft-com:office:word" xmlns:m="http://schemas.microsoft.com/office/2004/12/omml" xmlns="http://www.w3.org/TR/REC-html40">
<head>
<meta http-equiv="Content-Type" content="text/html; charset=utf-8">
<meta name="Generator" content="Microsoft Word 15 (filtered medium)">
<style><!--
/* Font Definitions */
@font-face
{font-family:Wingdings;
panose-1:5 0 0 0 0 0 0 0 0 0;}
@font-face
{font-family:"Cambria Math";
panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
{font-family:Calibri;
panose-1:2 15 5 2 2 2 4 3 2 4;}
@font-face
{font-family:Palatino;}
/* Style Definitions */
p.MsoNormal, li.MsoNormal, div.MsoNormal
{margin:0in;
margin-bottom:.0001pt;
font-size:12.0pt;
font-family:"Calibri",sans-serif;}
a:link, span.MsoHyperlink
{mso-style-priority:99;
color:#0563C1;
text-decoration:underline;}
span.EmailStyle19
{mso-style-type:personal-reply;
font-family:"Calibri",sans-serif;
color:#1F497D;}
.MsoChpDefault
{mso-style-type:export-only;
font-size:10.0pt;}
@page WordSection1
{size:8.5in 11.0in;
margin:1.0in 1.0in 1.0in 1.0in;}
div.WordSection1
{page:WordSection1;}
/* List Definitions */
@list l0
{mso-list-id:138768941;
mso-list-template-ids:-244256722;}
@list l0:level1
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l0:level2
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:1.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l0:level3
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:1.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l0:level4
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l0:level5
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l0:level6
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l0:level7
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l0:level8
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l0:level9
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l1
{mso-list-id:2116556015;
mso-list-template-ids:2071631008;}
@list l1:level1
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l1:level2
{mso-level-number-format:bullet;
mso-level-text:o;
mso-level-tab-stop:1.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:"Courier New";
mso-bidi-font-family:"Times New Roman";}
@list l1:level3
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:1.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l1:level4
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l1:level5
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l1:level6
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l1:level7
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l1:level8
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l1:level9
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
ol
{margin-bottom:0in;}
ul
{margin-bottom:0in;}
--></style><!--[if gte mso 9]><xml>
<o:shapedefaults v:ext="edit" spidmax="1026" />
</xml><![endif]--><!--[if gte mso 9]><xml>
<o:shapelayout v:ext="edit">
<o:idmap v:ext="edit" data="1" />
</o:shapelayout></xml><![endif]-->
</head>
<body lang="EN-US" link="#0563C1" vlink="#954F72">
<div class="WordSection1">
<p class="MsoNormal"><span style="font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino"><a href="https://urldefense.com/v3/__https://moore-patientcare.smapply.io/prog/request_for_proposals/__;!!PhOWcWs!mbArIFV9CqT1BOxOKMmYmSpxXyTJ3Apcar_PGPQPf4QTFnm0xvjR9ld8HNNJbzxDvXNoQM9-plZz05rObDQ$" target="_blank">Gordon and Betty Moore Foundation: Development of Clinical Quality Measures to Improve Diagnosis</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">In November 2018, the Moore Foundation announced its <a href="https://urldefense.com/v3/__https://www.moore.org/article-detail?newsUrlName=the-moore-foundation-invests-$85-million-to-improve-diagnostic-performance__;!!PhOWcWs!mbArIFV9CqT1BOxOKMmYmSpxXyTJ3Apcar_PGPQPf4QTFnm0xvjR9ld8HNNJbzxDvXNoQM9-plZzZz6Hu98$" target="_self">Diagnostic
Excellence Initiative</a>, which aims to reduce harm from erroneous or delayed diagnoses, reduce costs and redundancy in the diagnostic process, improve health outcomes, and save lives. According to the foundation, twelve million Americans experience a diagnostic
error each year, with diagnostic errors playing a role in an estimated 40,000 to 80,000 deaths annually in the U.S. In short, there is an urgent need to improve diagnosis; however, without an awareness of baseline performance and standards against which to
compare performance, there is no way to measure improvement or to gauge the results of interventions. Despite a lengthy and growing list of clinical quality measures in health care, few existing measures address diagnostic performance specifically. The challenge
of finding meaningful clinical measures for diagnosis reflects the complexity of the diagnostic process. To that end, grants of up to $500,000 over eighteen months will be awarded to support the development of innovative clinical quality measures that promote
excellence in diagnosis of three categories of disease, acute vascular events (such as stroke and myocardial infarction), infections (such as sepsis and pneumonia), and cancer (such as lung and colorectal cancer). The expected work requires two interlinked
activities: 1) development of the rationale for a measure, and 2) operationalizing the measure into an algorithm that can undergo pilot (or proof-of-concept) testing. Proposals should include teams and partnerships that include a multidisciplinary group of
experts, including clinicians with content expertise, individuals with appropriate analytic expertise (data science, statistics, measure development), and persons with experience using relevant data sources.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino">Due May 4, 2020. <span style="color:red">
Med-RA deadline to receive draft documents: April 21.</span></span></b><span style="font-size:11.0pt"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino"><a href="https://urldefense.com/v3/__https://www.aacr.org/Funding/Pages/Funding-Detail.aspx?ItemID=90__;!!PhOWcWs!mbArIFV9CqT1BOxOKMmYmSpxXyTJ3Apcar_PGPQPf4QTFnm0xvjR9ld8HNNJbzxDvXNoQM9-plZzWyx1ivw$" target="_blank">American Association for Cancer Research: Transformative Cancer Research</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">The AACR NextGen Grants for Transformative Cancer Research represent a funding initiative to stimulate highly innovative research from young investigators. This grant mechanism is intended to promote and
support creative, paradigm-shifting cancer research that may not be funded through conventional channels. It is expected that these grants will catalyze significant scientific discoveries and help talented young investigators gain scientific independence.
The proposed research must represent a highly innovative approach to a major challenge in cancer and have the potential to lead to groundbreaking discoveries in the field and transform our understanding of the tumorigenesis process and/or our ability to treat,
detect, or prevent cancer. The research can be in any area of basic, translational, or clinical science, but at least one AACR NextGen Grant will be awarded to a breast cancer-focused project. Though the program, grants of up to $450,000 over three years will
be awarded for any type of basic, translation, or clinical research.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino">Letter of intent due May 5, 2020.
<span style="color:red">Med-RA deadline to receive draft documents: April 22.</span><o:p></o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-family:Palatino"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><span style="font-family:Palatino"><a href="https://urldefense.com/v3/__https://donaghue.org/grant-opportunities/greater-value-portfolio/__;!!PhOWcWs!mbArIFV9CqT1BOxOKMmYmSpxXyTJ3Apcar_PGPQPf4QTFnm0xvjR9ld8HNNJbzxDvXNoQM9-plZz0WrL4aw$" target="_blank">Donaghue Foundation: Higher Value Healthcare System</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">The Donaghue Foundation seeks to be an imaginative, collaborative, and engaged participant in the process that begins with rigorous health research and ends in realized health benefits. To advance this
mission, the foundation is inviting applications for its 2020 Greater Value Portfolio grant program. The goal of the program is to test approaches and tools that organizations can readily use to improve the value of the health care they provide to their patients
and communities. To that end, grants of up to $400,000 over up to two years will be awarded in support of promising approaches designed to help create a higher value healthcare system. The proposed research should be focused on developing actionable solutions
to one or more of the symptoms of low value health care: high and rising healthcare costs; unwarranted variation in prices; unaffordable cost of care burden on patients and families; unacceptable variation in quality; and/or lack of transparency in both price
and outcomes. Eligible approaches include models of care, coverage, or system change that seek to improve value by addressing one or more of the symptoms of low value and/or reduce routine treatments, tests, and screenings for patients for whom the potential
harms (including financial harm) outweigh potential benefits; provide tools to help consumers make decisions about their healthcare based on value, including the cost of care to patients (in addition to other patient-centered factors); promote conversations
between patients and their clinicians and care teams about preferences and trade-offs related to alternative treatment options and /or out of pocket cost burden to patients and families; and/or test interventions geared to reducing racial and ethnic disparities
through the provision of higher value healthcare.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino">Letter of intent due May 11, 2020.
<span style="color:red">Med-RA deadline to receive draft documents: April 28.</span></span></b><span style="font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino"><a href="https://urldefense.com/v3/__https://www.michaeljfox.org/grant/parkinsons-pathway-biomarkers__;!!PhOWcWs!mbArIFV9CqT1BOxOKMmYmSpxXyTJ3Apcar_PGPQPf4QTFnm0xvjR9ld8HNNJbzxDvXNoQM9-plZzJTBZTTM$" target="_blank"><span style="color:#1F497D">Michael J. Fox Foundation: Parkinson’s Pathway Biomarkers</span></a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">According to the foundation, many current Parkinson’s research efforts are focused on understanding the role of various cellular processes/pathways in PD and uncovering novel targets within these pathways
for therapeutic development. As such, sensitive biomarker readouts for these pathways will be critical for bridging the gap from basic to translational research and clinical trials. The Parkinson’s Pathway Biomarkers program is open to industry and academic
investigators proposing studies aimed at developing sensitive readouts for pathway activation/dysfunction and improving technologies for analyzing the target/pathway of interest.<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">Through the program, grants of up to $300,000 will be awarded in support of studies in one or more of the following areas: biomarker studies focused on pathways that are known to be affected in PD (e.g.,
inflammation, mitochondrial function, lysosomal function, autophagy, protein trafficking, protein handling); studies aimed at developing novel pathway-based outcome measures or biochemical assays for PD; studies optimizing existing assays to assess PD-related
pathways or pathway-based targets; and studies investigating translational biomarkers that can be assessed in preclinical models as well as patient samples. Proposals submitted for the program should focus on the development of biomarkers for pathways/targets
with established relevance to PD.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino">Pre-proposal due May 14, 2020.
<span style="color:red">Med-RA deadline to receive draft documents: May 4.</span><o:p></o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-family:Palatino"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><span style="font-family:Palatino"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/rfa-files/RFA-AA-20-008.html__;!!PhOWcWs!mbArIFV9CqT1BOxOKMmYmSpxXyTJ3Apcar_PGPQPf4QTFnm0xvjR9ld8HNNJbzxDvXNoQM9-plZzfeMGdKw$" target="_blank">Collaborative Initiative on Fetal Alcohol Spectrum Disorders (CIFASD) Exploratory/Developmental Research Projects
(UH2 Clinical Trial Optional)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">The National Institute on Alcohol Abuse and Alcoholism (NIAAA) solicits research applications to address significant challenges in Fetal Alcohol Spectrum Disorders (FASD) research in the areas of diagnosis/screening,
etiology, interventions and treatment. Cooperative Agreement (UH2) applications in response to this FOA should propose exploratory/developmental projects, based on new and innovative concepts, approaches, and technologies. This solicitation is open to all
eligible institutions. To maximize the impact of their research, awardees will be encouraged to establish a collaborative relationship with the NIAAA-supported Collaborative Initiative on Fetal Alcohol Spectrum Disorders (CIFASD) consortium.<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">For this FOA no preliminary data are required, expected, or encouraged. However, if available, minimal preliminary data are allowed.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino">Due May 19, 2020. <span style="color:red">
Med-RA deadline to receive draft documents: May 6.</span></span></b><span style="font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/pa-files/PA-20-162.html__;!!PhOWcWs!mbArIFV9CqT1BOxOKMmYmSpxXyTJ3Apcar_PGPQPf4QTFnm0xvjR9ld8HNNJbzxDvXNoQM9-plZz08u-c_4$" target="_blank">Ruth L. Kirschstein National Research Service Award (NRSA) Short-Term Institutional Research Training Grant (Parent
T35)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">The National Institutes of Health (NIH) will award Ruth L. Kirschstein National Research Service Award (NRSA) Short-Term Institutional Research Training Grants (T35) to eligible, domestic institutions
to develop and/or enhance research training opportunities for predoctoral students interested in careers in biomedical, behavioral, or clinical research. Many NIH Institutes and Centers (ICs) use this NRSA program exclusively to support intensive, short-term
research training experiences for health professional students (medical students, veterinary students, and/or students in other health-professional programs) during the summer. This program is also intended to encourage training of graduate students in the
physical or quantitative sciences to pursue research careers by short-term exposure to, and involvement in, the health-related sciences. The training should be of sufficient depth to enable the trainees, upon completion of the program, to have a thorough exposure
to the principles underlying the conduct of biomedical research.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino">Standard dates apply. Expires May 8, 2023.
<span style="color:red">Med-RA deadline to receive draft documents for May 25, 2020 standard date: May 12.</span><o:p></o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-family:Palatino"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><span style="font-family:Palatino"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/rfa-files/RFA-MD-20-008.html__;!!PhOWcWs!mbArIFV9CqT1BOxOKMmYmSpxXyTJ3Apcar_PGPQPf4QTFnm0xvjR9ld8HNNJbzxDvXNoQM9-plZzozqeaPM$" target="_blank">Addressing Racial Disparities in Maternal Mortality and Morbidity (R01 Clinical Trial Optional)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">This initiative will support multidisciplinary research examining mechanisms underlying racial and ethnic disparities in maternal mortality and morbidity, testing the efficacy and/or effectiveness of multi-level
interventions, and/or research strategies to optimally and sustainably deliver proven-effective prevention and treatment interventions to reduce these disparities.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino">Due May 29, 2020. <span style="color:red">
Med-RA deadline to receive draft documents: May 18.</span></span></b><span style="font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><span style="font-family:Palatino"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/rfa-files/RFA-MH-20-525.html__;!!PhOWcWs!mbArIFV9CqT1BOxOKMmYmSpxXyTJ3Apcar_PGPQPf4QTFnm0xvjR9ld8HNNJbzxDvXNoQM9-plZzX3Ibxfw$" target="_blank">NIMH Biobehavioral Research Awards for Innovative New Scientists (NIMH BRAINS) (R01 Clinical Trial Optional)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">The NIMH Biobehavioral Research Awards for Innovative New Scientists (BRAINS) award is intended to support the research and research career advancement of outstanding, exceptionally productive scientists
who are in the early, formative stages of their careers and who plan to make a long-term career commitment to research in specific mission areas of the NIMH. This award seeks to assist these individuals in launching an innovative clinical, translational, basic,
or services research program that holds the potential to profoundly transform the understanding, diagnosis, treatment, or prevention of mental disorders. The NIMH BRAINS program will focus on the research priorities and gap areas identified in the NIMH Strategic
Plan.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino">Due June 20, 2020; June 20, 2021; and June 20, 2022.
<span style="color:red">Med-RA deadline to receive draft documents for June 20, 2020 due date: June 9.</span></span></b><span style="font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-family:Palatino">Paralyzed Veterans of America Research Fellowships and Grants: Spinal Cord Injury and Disease<o:p></o:p></span></b></p>
<p class="MsoNormal"><span style="font-family:Palatino"><a href="https://urldefense.com/v3/__https://www.pva.org/research-foundation__;!!PhOWcWs!mbArIFV9CqT1BOxOKMmYmSpxXyTJ3Apcar_PGPQPf4QTFnm0xvjR9ld8HNNJbzxDvXNoQM9-plZzN5y2z9Y$" target="_blank">Overview</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino"><a href="https://urldefense.com/v3/__https://pva-cdnendpoint.azureedge.net/prod/libraries/media/pva/library/pdfs/fy2021-pva-research-foundation-policies-and-procedures.pdf__;!!PhOWcWs!mbArIFV9CqT1BOxOKMmYmSpxXyTJ3Apcar_PGPQPf4QTFnm0xvjR9ld8HNNJbzxDvXNoQM9-plZzsrupwtU$" target="_blank">Policies and Procedures</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">From transplanting cells and regenerating damaged nerve fibers to designing adaptive canoe seats, the Paralyzed Veterans of America Research Foundation supports innovative research and fellowships that
improve the lives of those with spinal cord injury and disease (SCI/D). The Research Foundation, a 501(c)(3) nonprofit, funds the following categories:<o:p></o:p></span></p>
<ul style="margin-top:0in" type="disc">
<li class="MsoNormal" style="mso-list:l1 level1 lfo3"><b><span style="font-family:Palatino">Basic Science</span></b><span style="font-family:Palatino"> - laboratory research in the basic sciences to find a cure for SCI/D. Grants funded up to $75,000 for 1 year
or up to $150,000 for 2 years.<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l1 level1 lfo3"><b><span style="font-family:Palatino">Clinical</span></b><span style="font-family:Palatino"> - clinical and functional studies of the medical, psychosocial and economic effects of SCI/D, and interventions
to alleviate these effects. Grants funded up to $75,000 for 1 year or up to $150,000 for 2 years.<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l1 level1 lfo3"><b><span style="font-family:Palatino">Design & Development / Assistive Technology</span></b><span style="font-family:Palatino"> - of assistive technology for people with SCI/D, which includes improving
the identification, selection and utilization of these devices. Grants funded up to $75,000 for 1 year or up to $150,000 for 2 years.<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l1 level1 lfo3"><b><span style="font-family:Palatino">Postdoctoral Fellowships</span></b><span style="font-family:Palatino"> - for postdoctoral scientists, clinicians and engineers to encourage training and specialization
in the field of spinal cord research. Grants funded up to $50,000 for 1 year or up to $100,000 for 2 years.<o:p></o:p></span></li></ul>
<p class="MsoNormal"><b><span style="font-family:Palatino">Due July 1, 2020. <span style="color:red">
Med-RA deadline to receive draft documents: June 18.</span><o:p></o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-family:Palatino"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><span style="font-family:Palatino"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-20-030.html__;!!PhOWcWs!mbArIFV9CqT1BOxOKMmYmSpxXyTJ3Apcar_PGPQPf4QTFnm0xvjR9ld8HNNJbzxDvXNoQM9-plZzxJKfDxg$" target="_blank">Utilizing Cohort Studies to Address Health Outcomes in Cancer Survivors (UG3 / UH3 Clinical Trial Not Allowed)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) invites applications to support research in new and innovative cohort studies that identify clinical, lifestyle,
genomic, and other factors that affect health outcomes (e.g., morbidity, mortality, quality of life, physical, social, and psychological outcomes) in cancer survivors (i.e., from diagnosis to the end of life). This FOA intends to support research that requires
the creation of a new prospective cohort study that addresses a gap in knowledge pertaining to the health of cancer survivors. Applications must identify the scientific gap that the study addresses, which may include emerging treatments, less common cancer
sites, and/or understudied populations of cancer survivors with disparities. Sample size and proposed data collection must be driven by the scientific questions proposed and should include information from all the following five domains in order to cover the
full extent of the cancer survivor experience: 1) disease characteristics (e.g., type, stage, tumor biomarkers), 2) individual survivor characteristics (e.g., comorbidities, socioeconomic status [SES], social connections, information seeking, access to care
measures), 3) treatment, treatment-related effects, and follow-up care (e.g. dose, adverse events, palliative care), 4) behavioral and lifestyle factors (e.g., diet, physical activity, adherence) and 5) quality of life outcomes (health-related quality of life
(HRQOL), patient symptom reports). These domains may represent exposures and/or outcomes, depending on the research questions, and should be measured at multiple timepoints, when appropriate. The UG3/UH3 mechanism has two phases: the UG3 Planning-Exploratory
Phase focused on the recruitment of study participants and data collection/utilization, and the UH3 Implementation Phase focused on completing the research agenda. Milestones to be accomplished in the UG3 phase for transition to the UH3 phase should be proposed
by the Principal Investigator(s) (PIs), which will require NCI review and approval before the grant is awarded , and must include a timeline for recruitment and show feasibility for data collection and analysis. Recruitment is not required to be completed
in the UG3 phase, but reasonable progress should be demonstrated to ensure that all aims will be completed in the UH3 phase.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino">Due July 7, 2020. <span style="color:red">
Med-RA deadline to receive draft documents: June 25.</span></span></b><span style="font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/pa-files/PAR-20-164.html__;!!PhOWcWs!mbArIFV9CqT1BOxOKMmYmSpxXyTJ3Apcar_PGPQPf4QTFnm0xvjR9ld8HNNJbzxDvXNoQM9-plZz300p844$" target="_blank">Mechanisms and Consequences of Sleep Disparities in the U.S. (R01 – Clinical Trial Not Allowed)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">The purpose of this Funding Opportunity Announcement is to promote research to understand the underlying mechanisms of sleep deficiencies among U.S. populations that experience health disparities and how
sleep deficiencies may lead to disparities in health outcomes.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino">July 14, 2020; July 14, 2021; and July 14, 2022.
<span style="color:red">Med-RA deadline to receive draft documents for July 14, 2020 due date: June 29.</span><o:p></o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-family:Palatino"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><span style="font-family:Palatino"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-20-029.html__;!!PhOWcWs!mbArIFV9CqT1BOxOKMmYmSpxXyTJ3Apcar_PGPQPf4QTFnm0xvjR9ld8HNNJbzxDvXNoQM9-plZze6_s3Ps$" target="_blank">BRAIN Initiative: Exploratory Team-Research BRAIN Circuit Programs – eTeamBCP (U01 Clinical Trials Optional)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">This funding opportunity announcement (FOA) is designed to support teams of investigators that seek to cross boundaries of interdisciplinary collaboration to elucidate the contributions of dynamic circuit
activity to a specific behavioral or neural system. Applications are encouraged to propose adventurous and challenging goals that can only be tackled by a synergistic team-based approach and have the potential to be transformative and/or to enable significant
advances. These studies at the exploratory stage are intended for the development of experimental capabilities and/or theoretical frameworks in preparation for a future competition for larger-scale or extended efforts, including the BRAIN TargetedBCP R01 or
the multi-component, Team-Research BRAIN Circuit Programs (U19). The overall goal of this FOA is to enable a large-scale analysis of neural systems and circuits within the context and during the simultaneous measurement of an ethologically relevant behavior.
Toward this end, teams are expected to assemble and leverage multi-disciplinary expertise, and to integrate experimental with computational and theoretical approaches. Teams are expected to bridge fields by incorporating rich information on cell-types, on
circuit functionality and connectivity, in conjunction with sophisticated analyses of an ethologically relevant behavior of an organism or a well-defined neural system. Teams are also expected to aim for a mechanistic understanding of the circuits of the central
nervous system (CNS) by applying cutting-edge methods such as those for large-scale recording, manipulation, and analysis of neural circuits across multiple regions of the CNS.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino">Due July 14, 2020 and June 15, 2021.
<span style="color:red">Med-RA deadline to receive draft documents for July 14, 2020 due date: June 29.</span></span></b><span style="font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino">New Congressionally Directed Medical Research Program Announcements<o:p></o:p></span></b></p>
<p class="MsoNormal"><span style="font-family:Palatino"><a href="https://urldefense.com/v3/__https://cdmrp.army.mil/funding/prmrp__;!!PhOWcWs!mbArIFV9CqT1BOxOKMmYmSpxXyTJ3Apcar_PGPQPf4QTFnm0xvjR9ld8HNNJbzxDvXNoQM9-plZzMevYB9Q$" target="_blank">Peer Reviewed Medical Research Program</a><o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino">Clinical Trial Award</span></b><span style="font-family:Palatino"><br>
Pre-application (letter of intent): July 29, 2020. Application: August 13, 2020. <o:p>
</o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino;color:red">Med-RA deadline to receive draft documents for application: August 3.</span></b><span style="font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino">Clinical Trial Award (for Emerging Viral Diseases and Respiratory Health)</span></b><span style="font-family:Palatino"><br>
Pre-application (letter of intent): June 8, 2020. Application: June 22, 2020. <o:p>
</o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino;color:red">Med-RA deadline to receive draft documents for application: June 9.</span></b><span style="font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino">Investigator-Initiated Research Award (for Emerging Viral Diseases and Respiratory Health)</span></b><span style="font-family:Palatino"><br>
Pre-application (letter of intent): May 28, 2020. Application: June 12, 2020. <o:p>
</o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino">Technology/Therapeutic Development Award (for Emerging Viral Diseases and Respiratory Health)</span></b><span style="font-family:Palatino"><br>
Pre-application (letter of intent): May 28, 2020. Application: June 12, 2020. <o:p>
</o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino;color:red">Med-RA deadline to receive draft documents for application: June 1.</span></b><span style="font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino"><a href="https://urldefense.com/v3/__https://cdmrp.army.mil/funding/ocrp__;!!PhOWcWs!mbArIFV9CqT1BOxOKMmYmSpxXyTJ3Apcar_PGPQPf4QTFnm0xvjR9ld8HNNJbzxDvXNoQM9-plZzSQowdzM$" target="_blank">Ovarian Cancer Research Program</a><o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino">Proteogenomics Research Award<br>
</span></b><span style="font-family:Palatino">Pre-application: July 16, 2020. Application: July 30, 2020.
<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino;color:red">Med-RA deadline to receive draft documents for application: July 20.</span></b><b><span style="font-family:Palatino"><o:p></o:p></span></b></p>
<p class="MsoNormal"><span style="font-family:Palatino"><a href="https://urldefense.com/v3/__https://cdmrp.army.mil/funding/tscrp__;!!PhOWcWs!mbArIFV9CqT1BOxOKMmYmSpxXyTJ3Apcar_PGPQPf4QTFnm0xvjR9ld8HNNJbzxDvXNoQM9-plZz45ujNds$" target="_blank">Tuberous Sclerosis Complex Research Program</a><b><br>
Exploration Hypothesis Development Award<br>
</b>Pre-application (letter of intent): June 18, 2020. Application: July 9, 2020.<b><br>
Idea Development Award<br>
</b>Pre-application (letter of intent): June 18, 2020. Application: July 9, 2020.
<br>
<b>Clinical Translational Research Award<br>
</b>Pre-application (letter of intent): June 18, 2020. Application: July 9, 2020.
<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino;color:red">Med-RA deadline to receive draft documents for application: June 29.</span></b><span style="font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino"><a href="https://urldefense.com/v3/__https://cdmrp.army.mil/funding/prorp__;!!PhOWcWs!mbArIFV9CqT1BOxOKMmYmSpxXyTJ3Apcar_PGPQPf4QTFnm0xvjR9ld8HNNJbzxDvXNoQM9-plZzbSyShVg$" target="_blank">Prostate Cancer Research Program</a><br>
<b>Idea Development Award</b><br>
Pre-application (preproposal): August 27, 2020. Application: September 24, 2020. <o:p>
</o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino;color:red">Med-RA deadline to receive draft documents for application: September 14.</span></b><span style="font-family:Palatino"><br>
<b>Clinical Trial Award</b><br>
Pre-application (letter of intent): June 25, 2020. Application: July 16, 2020. <br>
<b>Health Disparity Research Award</b><br>
Pre-application (letter of intent): June 25, 2020. Application: July 16, 2020.<br>
<b>Population Science and Outcomes Research Award</b><br>
Pre-application (letter of intent): June 25, 2020. Application: July 16, 2020.<br>
<b>Translational Science Award</b><br>
Pre-application (letter of intent): June 25, 2020. Application: July 16, 2020.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino;color:red">Med-RA deadline to receive draft documents for application: July 6.</span></b><span style="font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino">To search for additional funding opportunities, please visit <a href="https://urldefense.proofpoint.com/v2/url?u=https-3A__fsucomgrants.wordpress.com_&d=DwMGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=-WQkPIXZLCgXlX-d14DY8B-SG-GvP9FZHr_Gv8sUuTQ&s=ErAzzubGxiJsWCKGnlFjfXV6980C-DCl-AxzFLHMVYQ&e=" title="https://urldefense.proofpoint.com/v2/url?u=https-3A__fsucomgrants.wordpress.com_&d=DwMGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=-WQkPIXZLCgXlX-d14DY8B-SG-GvP9FZHr_Gv8sUuTQ&s=ErAzzubGxiJsWCKGnlFjfXV69">CoM’s
unofficial funding opportunities blog</a>.<o:p></o:p></span></b></p>
</div>
</body>
</html>